Safety and Effectiveness of Radiofrequency Ablation System in the Treatment of Peripheral Lung Tumors

Exclusion Criteria

• •1. Subjects with severe bleeding tendency and irreversible clotting disorders; or subjects who have stopped anticoagulation therapy and/or antiplatelet drugs for less than 7 days before ablation;
• •2. Subjects whose preoperative examination within 1 month shows intrathoracic lymph node or extra-pulmonary metastasis (except for extra-pulmonary metastasis controlled by local therapy);
• •3. Planned ablated lesions have received radiotherapy within past 6 months;
• •4. Subjects with high-risk disease for ablation operation;
• •5. The nearest distance between the tumors and trachea, main bronchial tube, esophagus, aortic arch branch, main pulmonary artery, left and right pulmonary artery and the heart is less than 2cm;
• •6. Subjects who have participated in the last 30 days or is participating in other clinical studies;
• •7. Subjects who are pregnant or have pregnancy plan during the study;
• •8. Subjects with bronchoscopy contraindications;
• •9. Subjects with implantable cardiac pacemakers, implantable defibrillators, or other active implants;
• •10. Subjects with general anesthesia contraindications;
• •11. Subjects with other conditions that need to be excluded as determined by investigators.